This ad was created to support a new program by Biomedix

1. next-gen
product
new partner
program
A deadly chronic condition...
• 8-12 million Americans have
Peripheral Artery Disease (PAD)
• 75% of people with PAD have heart
disease
• 30% of those with PAD are likely to
die from a stroke or heart attack
within 5 years
Committed to saving limbs and
saving lives
Biomedix’s patented platform enables
community-based collaborative care
for the early detection of PAD, leading
to high-quality, cost- effective clinical
operations.
A next-generation product and
our new PARTNERS Program
Our commitment to saving limbs and
lives has led to our latest generation
PADnet - the PADnet 4.0 Vascular
Assessment System.
In addition, we are announcing an
all-new PARTNERS Program where
industry members can earn incentives
when teaming with us on this
important mission.
PADnet is...
Clinically Valuable
* ABI, TBI, PVR, & CVI
Easy-to-use
* Uses cuffs and PPG probes
Financially Sustainable
* Supports reimbursement of CPT codes 93922, 93923,
and 93924**
* Identifies HCC codes 108, 107, 106 and HCC 18
Biomedix Sales
877-854-0014
sales@biomedix.combiomedix
®
©2017 Collaborative Care Diagnostics, LLC dba Biomedix • PADnet is a registered trademark of Biomedix • ML-229 Rev A Jun 2017
PADNET: U.S. PATENTS 7,983,930; 8,229,762 B2; 7,214,192; 7,172,555; 7,166,076 & PATENTS PENDING.
* Please contact Biomedix sales for full details on this program.
** Reimbursement criteria & amounts are subject to change without notice.
PARTNERS
PROGRAM
biomedix
®
For every PADnet
referral*
Earn 7%